The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes by Kinalska, Ida et al.
International Scholarly Research Network
ISRN Endocrinology
Volume 2012, Article ID 625809, 5 pages
doi:10.5402/2012/625809
Review Article
The Inﬂuenceof IncretinMimetics on Cardiovascular Risk
Factors in Diabetes
Ida Kinalska,1 DorotaBednarska-Chabowska,2 JoannaAdamiec-Mroczek,3
andŁukaszHak4
1Clinic of Endocrinology Diabetology and Internal Medicine, Medical University of Bialystok, M.Curie-Sklodowska 24a,
15-269 Bialystok, Poland
2Clinic of Angiology, Arterial Hypertension and Diebetology, Medical Academy in Wroclaw, ul. Poniatowskiego 2,
50-326 Wrocław, Poland
3Clinic of Ophthalmology, Medical Academy in Wroclaw, ul. Borowska 213, 50-556 Wrocław, Poland
4Novo Nordisk Pharma Sp. z o.o., ul. 17 Stycznia 45B, 02-146 Warszawa, Poland
Correspondence should be addressed to Ida Kinalska, idakinal@op.pl
Received 26 October 2011; Accepted 1 December 2011
Academic Editors: C. Anderwald and A. Hishinuma
Copyright © 2012 Ida Kinalska et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors discuss the strategy of use of incretin hormones in type 2 diabetes treatment in the context of cardiovascular
complications. The results of the phase III study on human GLP-1 (Glucagon-like peptide-1) analogue-liraglutide have been
presented under common acronym LEAD (Liraglutide-Eﬀect and Action In Diabetes). The liraglutide therapy improved glycemic
control with low hypoglycemia risk and decreased glycated hemoglobin by an average 1,13%. Decreases in systolic pressure and
signiﬁcant body weight loss were observed. Not only did the index describing beta cells function HOMA-B improve but also
did the ratio of insulin to proinsulin. Summing up, incretin hormones beneﬁcially inﬂuence blood glucose level, moreover, their
use decreases blood pressure and body weight which might indicate their positive inﬂuence on cardiovascular system in diabetic
patients.
1.Introduction
Type 2 diabetes is related with the risk of cardiovascular
disease development which is the major cause of death
[1]. High risk of death and complications increased the
interest in introducing therapies which could not only give
the possibility of glycemic control but also could inﬂuence
the cardiovascular parameters. These possibilities give the
medications from the group of incretin mimetics.
The incretin hormones include Glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic peptide
(GIP). Intravenous administration of the incretin hormones
in patients suﬀering from type 2 diabetes causes the increase
in early-phase insulin secretion in response to a meal, but
only GLP-1 is able to stimulate insulin secretion in late phase
[2]. It is worth mentioning that the GIP level in patients
suﬀering from type 2 diabetes is similar to the one in healthy
people, however, for unknown reasons, it does not inﬂuence
bloodglucoseandinsulinlevel.Becauseofthesereasonsonly
GLP-1 has become a basis for new medication development
[3].
GLP-1 is secreted by L cells in small intestine and
duodenum. The secretion of this hormone is stimulated by
gastrointestinalpassageanddigestionprocess[4].GLP-1gets
to bloodstream and aﬀects a series of organs via its receptor.
From the glycemy regulation point of view, one of the most
important elements is the inﬂuence on the receptor in beta
pancreatic cells. Binding to the receptor stimulates insulin
secretion, GLP-1 is responsible for the secretion of 50 to 70%
of insulin in response to oral glucose administration [5].
It should be stressed that the insulin secretion stimulation
occurs exclusively when glucose level is elevated. Despite the
fact that in response to gastrointestinal passage stimulation,
quite big amount of GLP-1 hormone is secreted, only a small
part of it reach pancreatic islets. This happens because of
action of an enzyme dipeptidyl peptidase-4 (DPP-4) which
decomposes GLP-1 in blood within 2–4 minutes [6, 7].2 ISRN Endocrinology
The strategies of use of incretin hormones in type 2
diabetes treatment include the use of DPP-4 inhibitors and
exogenous GLP-1 substitution. Gliptins (DPP-4 inhibitors)
are the medications which by DPP-4 enzyme inhibition
increase endogenous GLP-1 level. These medications include
sitagliptin, wildagliptin and saxagliptin, and other sub-
stances undergoing clinical studies at the moment. These
medications decrease the level of secreted glucagon and
stimulate insulin secretion regulating glycemy [8]. The
second therapeutical strategy includes endogenous GLP-1
supplementation, currently registered medications include
human GLP-1 analogue (liraglutide, commercial name Vic-
toza) and GLP-1 receptor agonist (exenatide-commercial
name Byetta). Exenatide derives from saliva of a lizard Hila
Monster, the use of this medication results in body weight
loss and decrease in blood glucose level in patients suﬀering
from type 2 diabetes. What is more the use of exenatide
resulted in beta cells improvement. The exenatide half-life in
human body equals 60–90 minutes and its eﬀective activity
is 4–6 hours. Exenatide is administered twice daily [9].
Liraglutide (commercial name Victoza) is an analogue of
human GLP-1, in 97% homological with a native molecule.
Thediﬀerencesbetween native GLP-1 and liraglutide include
exchange of lysine to arginin in 34 position and addition
of glutamate to lysine in position 26; to glutamate also
was added 16C fatty acid-palmitic acid [6, 10]. After
subcutaneous administration, liraglutide forms heptameres
which slow down the release of the substance into the
bloodstream. In blood, liraglutide is reversibly connected to
albumins by the fatty acids. That is why liraglutide has 24
hour long action. It should be also stressed that introduced
modiﬁcations protect liraglutide from the action of the DPP-
4[ 6]. The medication is administered once daily in the doses
of 0.6mg (for at least a week), after a week, the patient
should augment the doses to 1.2mg, which is therapeutic
dose, however, it is also possible to take the doses of 1.8mg.
The III phase of clinical study of liraglutide has common
acronym LEAD (Liraglutide Eﬀect and Action in Diabetes)
included 4456 people. The LEAD program covered six
randomized studies analyzing the inﬂuence of drug admin-
istration at diﬀerent therapeutical stages of type 2 diabetes
treatment. The summary of the program is presented in
Table 1.Asitcanbenoticed,theliraglutidetherapyimproved
glycemic control reducing the level of glycated hemoglobin
byanaverage1,13%;thereductiondependedbothonfasting
glucose reduction and postprandial glucose reduction [11–
16].Duringthetherapywiththismedication,verylowriskof
hypoglycemia was proved which is related to the mechanism
of action of liraglutide, it reduces glycemy only on the
condition of elevated blood glucose level [13]. The eﬀect of
better glycemic control was accompanied by the reduction
in systolic blood pressure at an average by 3,41mmHg,
which can be considered as a protective action from further
diabetic complications such as cardiovascular complications
[11–16]. The use of liraglutide resulted also in body weight
loss and it should be stressed that the observed reduction
in arterial blood pressure was independent from the weight
loss. Moreover clinical indices describing beta cells function
such as HOMA-B and the ratio of proinsulin to insulin were
also improved in the whole period of liraglutide usage [14].
This indicates the improvement in beta cells function during
liraglutide use. It is also conﬁrmed by preclinical studies
which show the liraglutide treatment increase beta cells mass
in the animals with artiﬁcially destroyed pancreas [17].
The longest study LEAD-3 lasted for 52 weeks, the
remaining covered the period of 26 weeks of observation.
Part of these studies was prolonged in order to investigate
the eﬀects of the long-term eﬀect. The LEAD-6 studies and
its prolongation comparing liraglutide to exenatide showed
that it is currently the most eﬃcient molecule within the
family of GLP-1 receptor agonists [11]. Direct comparison
to exenatide in randomized clinical study showed that
mean HbA1c change equaled −1,1% in case of liraglutide
and −0,8% in case of exenatide whereas the change in
FPG equaled 1,61mmol/L (liraglutide) and 0,6mmol/L
(exenatide). Body weight loss equaled liraglutide—3,24kg
and exenatide—2,87kg, respectively. It should be stressed
that the use of both medications resulted in reduction
of systolic blood pressure but, in case of liraglutide, the
reduction equaled 2,51mmHg whereas exenatide reduced
systolic blood pressure by 2mmHg [11]. The prolongation
of this study by 14 weeks covered the transition of patients
using exenatide to liraglutide therapy. The results of this
study showed that the change of medication caused further
improvement of glycemic control: the HbA1c reduction,
FPG, and, moreover, further body weight loss and systolic
blood pressure reduction [18].
It should also be stressed that direct comparison of
liraglutide with sitagliptin showed advantage of GLP-1
analogue over DPP-4 inhibitor. The changes in HbA1c
equaled −1,5% and −1,24% for the doses of 1,8mg and
1,2mg of liraglutide, respectively, whereas sitagliptin caused
the reduction of HbA1c by −0,6%. During using liraglutide,
the body weight loss of −3.38kg (1,8mg doses), −2,86
(1,2mg doses) was observed, the reduction observed during
usage of sitagliptin 0,96kg [19]. The original study lasted
26 weeks and was extended to 1 year. The results of
extended study showed further advantage of liraglutide in
glycemic control, HbA1c reduction: −1.29% (1,2mg of
liraglutide), −1.51% (1,8mg of liraglutide) and −0.88%
(sitagliptin).Alsofurtherdiﬀerencesinbodyweightlosswere
observed: liraglutide 1.2mg (−2.78kg), 1.8mg (−3.68kg),
and sitagliptin (−1.16kg) (P<0.0001). Moreover, patients’
treatment satisfaction was higher, when liraglutide in the
doses of 1,8mg was used than sitagliptin [20].
The summary of the LEAD program showed that liraglu-
tide therapy cause body weight decreases. The reduction in
bodyweightdependsoninitialpatients’BMI,sobodyweight
reduction might be observed in obese patients, this eﬀect,
however,isnotobservedinpatientswithnormalbodyweight
[15]. Also, preclinical studies performed on rats showed that
peripheral liraglutide delivery results in body weight loss in
adult obese rats which was related to the reduction of food
supply and energy supply [21]. Liraglutide is an analogue
molecule to human native GLP-1 and the mechanisms
responsible for body weight loss are similar in case of both
molecules. These mechanisms also include the inﬂuence
on digestive system and central nervous system. LiraglutideISRN Endocrinology 3
Table 1: The summary of LEAD program. FPG—fasting plasma glucose, HbA1c—glycated hemoglobin, SBP—systolic blood pressure.
n
Mean change in
HbA1c from initial
values (%)
Mean change in FPG
from initial values
(mmol/L)
Mean change in body
weight from initial
values (kg)
Mean change of SBP
from initial values
(mmHg)
LEAD-3 (1573): Liraglutide in monotherapy versus glimepiride
Liraglutide 1,2mg 251 −0,8 −0,84 −2,05 −2,12
Liraglutide 1,8mg 247 −1,1 −1,42 −2,45 −3,64
Glimepirde 8mg 248 0,5 −0,29 +1,12 −0,69
LEAD-2 (1572): Liraglutide with metformin versus glimepiride
Liraglutide 1,2mg 241 −1 −1,64 −2,6 −2,8
Liraglutide 1,8mg 242 −1 −1,69 −2,8 −2,3
Glimepiride 4mg 244 −1 −1,31 +1 +0,4
LEAD-1 (1436): Liraglutide with glimeperide versus rosiglitazone
Liraglutide 1,2mg 228 −1,1 −1,57 +0,3 −2,6
Liraglutide 1,8mg 234 −1,1 −1,59 −0,2 −2,8
Rosiglitazone 4mg 232 −0,4 −0,88 +2,1 −0,9
Placebo 114 +0,2 +1,01 −0,1 −2,3
LEAD-4 (1574): Liraglutide with metformin and rosiglitazone versus placebo
Liraglutide 1,2mg 178 −1,5 −2,2 −1 −6,7
Liraglutide 1,8mg 178 −1,5 −2,4 −2 −5,6
Placebo 177 −0,5 −0,43 +0,6 −1,1
LEAD-6 (1797): Liraglutide with metformin and/or glimepiride versus exenatide
Liraglutide 1,8mg 233 −1,1 −1,61 −3,24 −2,51
Exenatide 10μg 231 −0,8 −0,6 −2,87 −2
causes reduction of the gastrointestinal passage and stomach
emptying [22]. This is one of the reasons of nausea in about
14% of patients during the ﬁrst month of the therapy, but
it should be pointed that nausea has transitional character
[12]. A relationship between the presence of nausea and
body weight loss has not been established; body weight loss
occurred both in patients experiencing nausea and in those
notexperiencingit.TheinﬂuenceonnervoussystemofGLP-
1 and liraglutide includes their inﬂuence on hunger/satiety
centersincentralnervoussystem[21,23].Bothmechanisms,
prolonged stomach emptying and satiety centre stimulation
in brain, result in the reduction of food intake and body
weight loss.
Liraglutide despite its obvious inﬂuence on body weight
isnotregisteredasanantiobesitymedication.However,there
are studies in which liraglutide action is compared to the
medications already registered as anti-obesity medications.
In 20 weeks long study, liraglutide was compared to orlisat;
the study showed that liraglutide more eﬃciently reduced
body weight in obese patients than orlistat and additionally
reduced blood pressure [24].
2. LiraglutideInﬂuenceon Cardiovascular
SysteminDiabetes
Beneﬁcial eﬀect of incretin medications on cardiovascular
system results both from direct and indirect inﬂuence on
heart and arterial system. The indirect eﬀect is the inﬂuence
onglycemiccontrolwiththelackoftheriskofhypoglycemia,
arterial blood pressure normalization, and body weight loss.
Lately, experimental studies have showed that GLP-1 exerts
direct beneﬁcial inﬂuence on cardiovascular system.
Liraglutide therapy lasting 26 weeks in patients suﬀering
from type 2 diabetes led to signiﬁcant cholesterol concen-
tration reduction, including LDL fraction, triglycerides, and
free fatty acids. The eﬀect mentioned above was proved in
meta analysis of all 6 LEAD studies [25].
Cummings et al. [26] focus on the fact that GLP-1
analogue administered once daily in patients with impaired
glucose tolerance or with diabetes de novo decreases
postprandial triglyceride, apolipoproteins: B-48, C III, and
also cholesterol and triglyceride remnants which results in
signiﬁcant reduction of cardiovascular complication risk
factors. According to Jendle et al. [27]e x c e p tf o rb o d yw e i gh t
loss, liraglutide is responsible for the reduction of fatty tissue
in body. In this analysis, a dual energy X-ray absorptiometry
(DEXA) was used. Fatty tissue reduction was related to
reduced production of aterogenous hormones and cytokines
by this organ. The authors at the same time conﬁrmed the
decrease in fatty liver in patients which beyond any doubt
is related to the improvement of sensitivity of this organ to
insulin action.
Plutzky et al. [25]c o n c e n t r a t e do nt h er e d u c t i o no f
independent arterial sclerosis risk factors such as C-reactive
protein (CRP) and brain natriuretic peptide (BNP). The
decrease in their concentration inhibits the inﬂammatory4 ISRN Endocrinology
cytokine activation directly engaged in vascular wall destruc-
tion.GLP-1analoguesmayinﬂuencetheearlystagesofatero-
genesis by inhibition of monocyte adhesion to the vascular
wall. It was shown on animal model deprived of apolipopro-
teinE.Subsequentinvivostudiesconﬁrmedliraglutideinﬂu-
ence on selected vascular endothelium destruction markers.
The use of liraglutide was related to TNF alfa inhibition
and hyperglycemia-dependant gene PAI-1, ICAM-1, VCAM-
1 induction in the cultures of human endothelial cells.
Molecularmechanismofthisprocesshasnotbeenexplained,
however, Liu et al. [28] revealed that liraglutide may regulate
expression of mRNA of NUR77 protein. This signal pathway
seems to play a key role in endothelial cells protection in
type 2 diabetes and in metabolic syndrome. At the same
time, observed increase in the production of nitric oxide
(NO) and inhibition of NF-κB partially by AMPK (AMP
activateproteinkinase),whichdocumentsanti-inﬂammatory
inﬂuence of liraglutide on vascular endothelium cells even
in hyperglycemia. The eﬀect mentioned above can explain
observed earlier vasodilative properties of the medication
and its beneﬁcial inﬂuence on cardiovascular system in
patients suﬀering from type 2 diabetes.
In 2009 Noyan-Ashraf et al. [29] conﬁrmed cardiopro-
tective prosperities of liraglutide in animal model. Smaller
cardiomyocytenecrosisareaintheinfarctzone,wasobserved
inmicetreatedbyliraglutideincomparisontomicereceiving
placebo. Liraglutide use was related to the improvement in
survival rate in comparison to placebo (80% versus 40%),
with decreased heart wall destruction risk, with reduction
of infarct zone and improvement in cardiac output [29].
Those data were conﬁrmed in pilot study where 10 high-
risk patients with acute myocardial infarction and systolic
dysfunction of left ventricle were subjected to 72 hour
long GLP-1 intravenous administration [30]. The authors
obtained total increase in left ventricle function which was
related to shorter period of hospitalization in comparison to
the patients with similar risk factors treated in a standard
way. Sokos et al. [31] infused GLP-1 in patients with III-
IV NYHA class up to 5 weeks. This allows obtaining a
signiﬁcantimprovementinleftventriclefunctionandgreater
life satisfaction in comparison to the control group.
The same group showed beneﬁcial inﬂuence of liraglu-
tide on the cardioprotective genes activity and expres-
sion (Akt, GSK3beta, PPAR-beta-delta, Nrf-2, and HO-
1). Cardioprotective eﬀect of liraglutide in comparison to
metformin was showed in induced myocardial infarction
in animals with diabetes, when similar metabolic control
was achieved. This may be explained by liraglutide action
on the increase of cAMP concentration and decrease of
caspase 3 activation responsible for the cardiomyocyte
apoptosis induction. This process was dependent on the
GLP-1 receptor [32].
In 1995 it was shown that GLP-1 receptors are active in
human heart muscle [33]. The studies of the following years
were concentrated on the beneﬁcial inﬂuence of GLP-1 on
left ventricle systolic function, heart muscle reperfusion in
chronic ischemia, and also in acute coronary syndrome [29–
31, 34, 35].
Liraglutide is an eﬃcient medication in the therapy of
patients suﬀering from type 2 diabetes. Retrospective anal-
yses of cardiovascular incidents during liraglutide therapy
showedthesafetyofthismedication[36,37].Fromthispoint
of view, the results of currently conducted study LEADER
(Liraglutide Eﬀect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results) will be very interesting,
the study in which 9000 of patients will be observed for the
periodof5years.Inthisstudy,partofthepatientswillreceive
liraglutide and part will be subjected to a standard anti-
type 2 diabetes therapy. The main aim of this study is the
determination of the liraglutide inﬂuence on cardiovascular
system. When we will have to wait for the outcomes of this
study, it is worth to stress that the data cited above suggest
cardioprotective action of the incretin based compunds.
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